CRISPR-Cas technologies: Emerging tools from research to clinical application
Journal of Microbiology · 31.08.2025 · 63 (8) · e2504012
DOI: 10.71150/jm.2504012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Microbiology, erschienen am 31.08.2025. Verfasst von Hana Hyeon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, Chung-Ang University, Seoul 06974, Republic of Korea. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, Genetic Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 350 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chung-Ang University, National Research Foundation of Korea, Ministry of Education.
Abstract (Originalsprache)
CRISPR-Cas technologies have emerged as powerful and versatile tools in gene therapy. In addition to the widely used SpCas9 system, alternative platforms including modified amino acid sequences, size-optimized variants, and other Cas enzymes from diverse bacterial species have been developed to apply this technology in various genetic contexts. In addition, base editors and prime editors for precise gene editing, the Cas13 system targeting RNA, and CRISPRa/i systems have enabled diverse and adaptable approaches for genome and RNA editing, as well as for regulating gene expression. Typically, CRISPR-Cas components are transported to the target in the form of DNA, RNA, or ribonucleoprotein complexes using various delivery methods, such as electroporation, adeno-associated viruses, and lipid nanoparticles. To amplify therapeutic efficiency, continued developments in targeted delivery technologies are required, with increased safety and stability of therapeutic biomolecules. CRISPR-based therapeutics hold an inexhaustible potential for the treatment of many diseases, including rare congenital diseases, by making permanent corrections at the genomic DNA level. In this review, we present various CRISPR-based tools, their delivery systems, and clinical progress in the CRISPR-Cas technology, highlighting its innovative prospects for gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Life Science, Chung-Ang University, Seoul 06974, Republic of Korea.
- Department of Microbiology, School of Medicine, Catholic University of Daegu, Daegu 42472, Republic of Korea.
- R & D Institute, NES Biotechnology, Seoul 06974, Republic of Korea.
Förderung
- Chung-Ang University
- National Research Foundation of Korea
- Ministry of Education
Zitieren
APA
Hyeon, H., Hwang, S., Luo, Y., Shin, E., Yeom, J. H., Kim, H. M., Ryu, M., & Lee, K. (2025). CRISPR-Cas technologies: Emerging tools from research to clinical application. Journal of Microbiology, 63(8), e2504012. https://doi.org/10.71150/jm.2504012
Vancouver
Hyeon H, Hwang S, Luo Y, Shin E, Yeom JH, Kim HM, et al. CRISPR-Cas technologies: Emerging tools from research to clinical application. Journal of Microbiology. 2025;63(8):e2504012. doi:10.71150/jm.2504012
BibTeX
@article{Hyeon2025,
author = {Hyeon, Hana and Hwang, Soonhye and Luo, Yongyang and Shin, Eunkyoung and Yeom, Ji-Hyun and Kim, Hong-Man and Ryu, Minkyung and Lee, Kangseok},
title = {CRISPR-Cas technologies: Emerging tools from research to clinical application},
journal = {Journal of Microbiology},
year = {2025},
volume = {63},
number = {8},
pages = {e2504012},
doi = {10.71150/jm.2504012}
}
EUVIMED